 baohuoside I-loaded mixed micelles,2
 single incision,2
 Sepsis,2
 genetics,2
PD-1,9
 PRAME antigen,2
 respiratory motion,3
 thymidylate synthase,3
 Ceritinib,8
Brain,4
 Neutropenia,3
heterogeneity,2
 migration,26
 iron,4
 Employment,2
 Inhalation,2
 Rac1,3
Pazopanib,2
 TNM classification,2
 nanoparticles,11
 quality of care,2
 pleurodesis,2
COX2,2
 tumor,6
 Second-line,2
 Pulmonary delivery,2
 Interstitial pneumonia,4
 cardiovascular disease,2
 screening,7
 Early detection,3
 macrophage,11
CRP,2
Combination therapy,2
 cryopreservation,2
 Embryonal rhabdomyosarcoma,2
 surveillance,4
 Triple-negative breast cancer,2
 TILs,2
 Synthesis,3
 nab-paclitaxel,3
Akt,5
 Silica,4
 EGFR‐TKI,2
 Radon,7
A549,10
 tumor suppressor gene,2
 autophagy,18
 non-small-cell lung cancer,56
cancer prognosis,2
 FDG-PET/CT,2
 c-Myc,3
 limited disease,2
 treatment outcome,2
 non small cell lung cancer,3
 supportive care,3
 Cost,3
 cigarette smoke,3
 infection,3
 Indoleamine 2,2
 intensive care unit,2
 Metronomic chemotherapy,2
Atezolizumab,2
 proliferation,20
 Case report,7
 Colon cancer,2
 recurrence,13
 Epigenetics,2
 adjuvant chemotherapy,6
 history,3
 systems biology,2
 peripheral lung lesion,2
 small cell lung cancer,15
 nuclear factor-κB,2
 Intrinsic pathway,2
 Pancreatic cancer,5
 β-Catenin,3
 malignant peritoneal mesothelioma,2
 Chronic obstructive pulmonary disease,4
 craniovertebral junction,2
 Single nucleotide polymorphism,2
 adjuvant therapy,2
 plasticity,2
 Lymphovascular invasion,2
Cervical cancer,4
Autoimmunity,2
cytology,3
 T790M,10
A549 cell,2
 Tumor suppressor,4
 lymphoma,4
 Cancer metabolism,2
C-reactive protein,2
 VEGF,8
 Uterus,2
 Triterpenoids,4
 India,3
ESMO,2
 Soft tissue sarcoma,6
 genotoxicity,3
 Asthma,2
 qualitative research,2
 mutations,5
 Vietnam,2
 Synthetic lethality,3
 PubChem CID,2
 Tin filtration,2
 ROCCs,2
 Interleukin-22,2
 mouse,2
 Exosomes,3
 comorbidity,2
 Chemoprevention,2
 Glucocorticoid receptor,2
 locally advanced,2
 Non-small-cell lung,4
 miR-200c,2
ADC,2
 Tubulin,2
BRCA,2
 Susceptibility,2
 chronic obstructive pulmonary disease,7
 hypoxia,5
 Non small cell lung cancer,3
 chrysotile,2
 Low/Middle income country,2
 SIRT1,3
 sputum,2
 Tumor marker,3
 pulmonary adenocarcinoma,2
 gene mutation,2
AKT,13
 cytopathology,2
 Platelets,2
 Thrombospondin-1,2
 Complete response,2
Immune checkpoint inhibitor,2
GGO,6
 lung function,4
 Predictors,2
 miR-26a,3
 Polyethylene glycol,2
 competing endogenous RNA,2
 skeletal metastasis,2
 Small cell lung carcinoma,8
MRI,2
 circulating tumor cells ,2
 Thymic carcinoma,5
 Outcomes research,2
Anxiety,3
 ginseng,2
 Flow cytometry,3
 Pleomorphic carcinoma,2
SNP,2
 SCLC,17
 mortality,20
 health services research,2
QOL,2
ATM,4
 circulating tumor cells,5
 tuberculosis,4
 chest radiography,2
 squamous cell carcinoma,16
 Neoplasm,4
 NQO1,2
 EGFR-TKI,8
 cancer monitoring,2
 Treatment,12
 Malignant pleural mesothelioma,8
NOX,2
 Cancer du poumon,5
 Time series,2
 Thorax,6
Cancer vaccines,3
Alectinib,4
 Immunothérapie,4
 teratoma,2
 sensitivity,2
 Pleura,7
 methylglyoxal,2
DNA methylation,12
 intervention,2
Antibacterial,3
circulating tumor cells,2
 Stereotactic,2
 NF1,2
 Pulmonary fibrosis,3
 fluorescence in situ hybridization,4
 Cytotoxicity,21
VILI,2
 cell invasion,2
DWI,2
FAK,4
 Lobectomy,7
 p21,2
 elderly,3
 Oxidative damage,2
 Lung resection,2
 ferroptosis,2
 Renal cell cancer,2
Drug delivery,4
 PC-9/GR cells,2
 Hepatitis B virus,2
 Cancer du sein,4
 Icotinib,2
Docetaxel,3
 Flavonoids,2
 Mental health,2
 Lung SBRT,2
Breast,3
 Thymus,3
PET,6
 Hyperthermia,2
 Metastases,11
MET,4
 Telomerase,2
 monoclonal antibody,5
 lung,38
 Neuroblastoma,3
 Collagen,2
 Elderly,8
 mitochondria,2
 FAK,3
Adenosine deaminase,2
 solid tumors,2
 treatment monitoring,2
 S-1,3
cigarette smoking,2
 GLUT1,2
Extracellular matrix,2
Lung,4
 Vascular invasion,2
 Prostaglandin E,2
18F-FDG PET,2
 next-generation sequencing,7
 Re-biopsy,2
 xenograft,2
 squamous cell,2
 TG-43,2
 Sorafenib,2
 NNK,2
 Target therapy,3
 metabolism,4
 adenocarcinoma,12
 Senescence,3
 lung adenocarcinoma,42
 microRNA ,3
 symptom management,3
 Trends,4
 peptide vaccine,3
 Targeted therapy,14
 Nanoparticle,3
 Cytokine-induced killer cells,2
 Genomic instability,2
 multidrug resistance,2
 Cancer,31
Colorectal neoplasm,2
 immune response,2
carbon nanotubes,2
Anti-angiogenesis,2
 Immunohistochemistry ,2
 Immunodeficiency,2
Colon cancer,4
3D cell culture,2
SIRT1,2
 CPSF4,2
 pathology,5
 hypoxia-inducible factor-1α,3
SPARC,2
 Cytokine,3
 longevity,2
 mTOR inhibitor,3
Carcinoembryonic antigen,2
 calcium,2
 small cell lung cancer ,4
 molecular targeted therapy,2
Cancer,61
Apoptosis,64
 Pulmonary,5
 coronary disease,2
 Paraneoplastic syndromes,2
 T cells,3
 Prodrug,2
 PCR,2
 Obesity,3
 rapamycin,2
 molecular diagnostics,2
 Lung tissue,2
adverse events,2
advanced non-small-cell lung cancer,2
ALK rearrangement,4
 triple negative breast cancer,3
 spinal laser interstitial thermotherapy,2
 Microwave ablation,2
NLR,2
Copper,3
 PET,13
 Prostate cancer,10
 diet,2
 Nedaplatin,2
 ROS1,7
 Biomarqueur,2
checkpoint inhibitors,3
 computed tomography ,3
 transbronchial needle aspiration,2
 Virtual screening,2
 lung cancer mortality,2
 Solitary pulmonary nodule,10
Bronchoscopy,6
 recombinant human endostatin,3
 tobacco control,2
 MTT,2
 long non-coding RNA,6
 Papillary thyroid carcinoma,2
 p38,2
Chemosensitivity,5
SNPs,2
 Pulmonary vein,2
 Classification,2
 staging,4
 selumetinib,2
 mass spectrometry,4
 pERK1/2,2
 Palliative radiotherapy,2
 Targeting,4
 drug resistance,23
 luteolin,3
 Pulmonary function,4
 Asian,2
pyrene,2
 Statins,2
Acute myeloid leukemia,4
 Curcumin,2
 Mass spectrometry,4
 Cancer cell lines,2
 education,2
 Systematic review,5
 tumor markers,2
 miRNA,13
Estrogen,2
 checkpoint inhibitors,4
 prognostic factors,5
 topoisomerase I,2
 Fibronectin,2
 lung injury,5
 Registry,2
Invasion,5
 risk assessment,2
 pemetrexed,13
EGFR,75
FGFR,2
 Pneumothorax,5
 PLR,2
 epithelial-mesenchymal transition ,2
 MMP,2
colorectal cancer,2
 Prognostic,2
 Phase 1,2
 second primary cancer,3
Prostate,2
Vaccines,2
 Protein,2
 shRNA,2
 Systemic lupus erythematosus,2
 Nrf2,9
 Phrenic nerve,2
 TKI,9
 Minimally invasive adenocarcinoma,3
 endothelin-1,3
 Species differences,2
 ONCOLOGY,2
Bisphosphonates,2
Adenocarcinoma of the lung,2
 shedding,2
 carboplatin,3
 predictive factors,2
 swi/snf,2
 EGFR protein,2
 melanoma,19
 Signaling pathway,2
 spinal metastases,2
A549 cells,8
 cell cycle,15
 kidney,3
 Tumor infiltrating lymphocytes,2
 IMRT,6
 polymorphism,9
 prognostic factor,6
 mediastinal,2
 Pronostic,3
Bioinformatics,3
 cell-free DNA,3
Thoracic surgery,3
CT scan,5
 robotic surgery,2
 miR-203,2
DICER1,2
GLUT1,2
P-glycoprotein,2
 nodules,3
 diagnosis,14
 Image registration,2
 vaccines,2
ROSE,2
 tumor growth,2
 Skin rash,2
 Standardized uptake value ,2
 Pembrolizumab,6
 thyroid cancer,4
 Plumbagin,2
invasion,2
miRNAs,2
 antibodies,2
 Thoracoscopy,2
 Histological type,2
 histone modification,2
 let-7,2
 prognostic biomarker,6
Non-small cell lung cancer,11
 subtype,2
 fluorescence in situ hybridisation,2
 mesothelin,2
 Interstitial lung disease,5
 Spleen,2
 DNA repair,4
 EMT,15
 chemosensitivity,2
 radiofrequency ablation,5
 decision making,3
CT-guided,2
 Proteomics,2
 Myeloid-derived suppressor cells,2
 methylation,3
 SINS ,2
 peptide,3
Air pollution,5
TPGS,2
 p53,24
 Circulating tumor DNA,2
 Monte Carlo,3
 LSD1,3
 MALAT1,8
 paraneoplastic,2
 TAS-102,2
 PARP inhibitor,2
 efficacy,3
 Osteosarcoma,7
 ruthenium,2
 Polymorphisms,3
Driver mutations,2
 idiopathic pulmonary fibrosis,4
 epithelial–mesenchymal transition,3
Nivolumab,3
 Fibrosis,4
malignancy,2
 hTERT,2
 Cancer stem cells,3
Acute lung injury ,2
 stereotactic ablative radiotherapy,2
 Epidermal growth factor,2
 chronic lung allograft dysfunction,2
 HDAC inhibitor,2
 Reproducibility,2
 cell cycle arrest,4
adenocarcinoma,11
Carcinoid,3
 imaging,2
 noncoding RNA,4
 Immuno-oncology,2
 thoracoscopy,3
 icotinib,4
 Cell viability,2
 complications,4
 Gastric cancer,5
 value of information,2
 non-small-cell lung carcinoma,2
 Sputum,2
Anticancer activity,5
 IL-23,2
 End-of-life care,3
 fibrosis,5
 CD133,3
5-fluorouracil,4
 pleural,3
Biocompatibility,2
Iran,2
 patritumab,2
 Cancer mortality,3
Epidermal growth factor receptor ,3
CTC,3
 epigenetics,8
 human epidermal growth factor receptor 2,2
 trastuzumab,3
 first line,2
 Macrophages,5
 Epidermal growth factor receptor tyrosine kinase inhibitor,2
 lungs,2
 Thymoma,9
 Radioresistance,2
 T790M mutation,3
 Lung Cancer,10
 Polymorphism,5
 Survivin,4
 exercise,3
 radiosensitivity,2
 tumor-associated macrophages,3
 nonsmall cell lung cancer,3
 Pulmonary toxicity,3
 Survival analysis,7
 interleukin-6,2
 renal angiomyolipoma,2
14-3-3ζ,3
 hexavalent chromium,2
 metastatic cancer,2
Diagnosis,8
 Chitosan,2
Differential diagnosis,2
 Meta-analysis,19
advanced cancer,2
 lung inflammation,3
 VATS lobectomy,2
ARDS,4
FFPE,2
 miR-21-PDCD4 signaling,2
 Knoevenagel condensation,2
 HGF,2
 Oxaliplatin,3
Heterogeneity,2
cancer stem cell,2
 Head and neck,2
 Thoracotomy,3
Epidermal growth factor receptor,8
 Silver nanoparticles,3
 photodynamic therapy,3
E1b,2
GGN,2
 Hepatocellular carcinoma,6
 irradiation,2
 physical activity,4
 Molecular dynamics,2
bone metastasis,3
 lymphadenectomy,2
 Pharmacokinetics,13
 Cisplatin resistance,3
 oxidative stress,4
 esophageal cancer,5
 Cancer broncho-pulmonaire,2
AF,2
 pH-responsive,2
Acute exacerbation,3
 epigenomics,2
 Sarcoidosis,2
HMGB1,4
Subxiphoid,2
 therapeutic antibody,2
 biomarkers,3
 fine needle aspiration,3
cfDNA,3
 Metastasectomy,5
 Synergistic effect,4
 predictors,2
 Gastrointestinal cancers,2
apoptosis,7
 cisplatin,10
Forecasting,2
 subxiphoid,2
 Quality assurance,2
 Pneumonia,9
 Dendritic cells,3
 immunity,3
 mTOR inhibitors,2
 exon 19 deletion,2
 incidence,11
 chemoresistance,8
 epithelial-mesenchymal transition,11
 Distant metastases,3
cost–benefit analysis,2
 Quality of Life,2
 oncology,13
 Adenocarcinoma,2
 Brain metastases,3
 Surveillance,4
 Resistance,10
 c-Met,3
 Antibiofilm,2
 oncogenesis,2
 Hsp90,2
 treatment,10
 distant metastasis,7
 PLCO,2
MMP9,2
 Intensity modulated radiotherapy,2
 MAPK,4
 electron microscopy,2
 Immunosuppression,3
 Lung adenocarcinoma,48
 adenocarcinoma of the lung,2
 Clinical trial,2
 Oligo-recurrence,2
 Stereotactic radiotherapy,3
 bone metastases,3
 Intensity-modulated radiotherapy,3
 Trachea,2
 Socioeconomic status,2
Chitosan nanoparticles,2
 phospholipids,2
 Chimiothérapie,2
TBNA,2
 Toxicity,16
 Early detection of cancer,2
 Chloroquine,3
 Osteopontin,3
Brain metastases,10
 Non-small-cell lung carcinoma,2
 sequencing,2
 radiosensitization,2
 lung cancer,380
 Neoplasm metastasis,3
 molecular testing,4
 pulmonary metastasis,3
 Risk score,2
 metastases,5
 heterogeneity,3
 Human,2
 qPCR,2
 telomerase,2
 Positron emission tomography ,3
 transplant,2
 radiomics,3
 tomography,4
 Photodynamic therapy,3
Adherence,2
 Benzimidazole,2
 Microenvironment,5
 Angiogenesis,5
Immunotherapy,6
 E-cadherin,2
 Respiratory motion,2
 EZH2,3
 colorectal cancer,11
 polymorphisms,2
 interplay effect,2
CTCs,3
 invadopodia,2
 A549,2
 Programmed cell death 1 receptor,2
 lncRNA,8
 growth,2
 Endothelial cells,2
 SUV,4
 cell apoptosis,2
 Pathology,6
Cancers bronchiques,2
 Staging,9
 Epidermal growth factor receptor mutation,2
Antimicrobial,2
 Rare lung tumors,2
 afatinib,12
 Durvalumab,2
 TNBC,2
 glioblastoma,3
 solitary pulmonary nodule,7
 Endostatin,2
 implementation,2
 WHO classification,2
 Tissue microarray,2
Cancer survivors,2
 RNA interference,3
TKI,6
 end-of-life care,2
 glutathione,5
 Surgical treatment,3
 pharmacokinetics,8
 miR-206,2
 lung neoplasm,4
 TAZ,2
 child,3
 Liver,2
 ramucirumab,2
 Life expectancy,3
MEK inhibitor,2
 colorectal carcinoma,2
 p300,2
 Thyroid gland,3
Biomarkers,13
 Metastasis,66
 Tumorigenesis,4
 epidermal growth factor receptor,19
EBUS,2
 SOX2,3
 bladder cancer,3
EGFR mutations,3
 non–small cell lung cancer,7
 Progression,2
ABCB1,2
 adverse effects,2
 immunotherapy,40
 survivin,4
 Antioxidant,2
 Frailty,2
 Hypofractionation,2
 AKT,2
 telomere,2
 Response,2
 Invasion,20
 cancer cells,6
Advanced cancer,3
 Oral squamous cell carcinoma,2
 immunohistochemistry ,3
 pulmonary alveolar proteinosis,2
Circulating tumor cells,4
CD44,5
 lipopolysaccharide,2
Economics,2
 Japanese,3
 Cervical cancer,2
Cancer stem cells,4
 targeting,2
 Adriamycin,2
EML4-ALK,2
 LUNG CANCER,5
PKR,2
IV,3
 monocytes,2
 video-assisted,3
 Migration,19
 Solid tumors,5
 circulating tumor DNA ,2
fibrosis,2
 Clinical trials,2
 Wnt,3
 non-small cell lung cancer ,30
 Iterative reconstruction,3
 epidemiology,14
 IHC,4
 Pleurodesis,4
 Stereotactic radiosurgery,2
 inhibitor,4
 HIF-1α,2
 liposomes,4
 IGF-1,4
 prevention,3
 prognostic marker,6
 follow-up,3
 NRAS,2
 Non-Small Cell Lung Cancer,4
 Immunotherapy,36
 NCI-H460,2
 PUMA,2
 small-cell lung cancer,11
 Treatment planning,4
 Mutation,5
 Protein-protein interactions,2
Anaplastic lymphoma kinase,10
 NTCP,2
PubChem CID,58
Video-assisted thoracic surgery ,4
 carcinoma,4
 postoperative complications,2
18F-fluorodeoxyglucose,4
advanced lung adenocarcinoma,2
 SABR,7
 stem cells,4
 Paraneoplastic,3
 Particulate matter,4
 nephrectomy,2
 Comprehensive genomic profiling,2
 ZEB1,2
 risk,6
 Risk prediction,2
 polymerase chain reaction,2
 Tumor-to-blood ratio,2
 dasatinib,2
 hospice,2
 first-line treatment,2
 GRB2,2
 Epidermal growth factor receptor ,7
 mice,3
 non-small lung cancer,2
 Genomics,3
 MTT assay,2
 pulmonary sclerosing hemangioma,2
 pulmonary disease,2
 Long noncoding RNA,4
Apolipoprotein A-I,2
 Tumor targeting,2
 p62,2
 Tuberculosis,10
 Patient preferences,3
 Phase II trial,3
 QALY,2
BRAF,7
 Tobacco,5
ALK status,2
 exon 19,2
 PET/MR,4
 nausea,2
 tumorigenicity,4
 tumor suppressor candidate 3,2
 Drug delivery,7
 segmentectomy,10
 outcome,6
 Capecitabine,2
 disparity,2
 Low-dose computed tomography,2
 Review,4
 T790 M,2
TKIs,2
 immunosurveillance,3
 radiation sensitivity,2
 Occupational exposure,3
ALI,3
AMPK,2
MDSCs,2
 Rectal cancer,2
 early detection,2
 Glioblastoma,4
 Comorbidity,5
 Plasma,3
 Lewis lung carcinoma,3
 cancer stem cells,5
 Prognosis,94
 Nasopharyngeal carcinoma,2
 Fluorescence in situ hybridization ,2
 advanced non-small cell lung cancer,2
 Metformin,5
 Liquid biopsy,5
 positron emission tomography ,2
AFAP1-AS1,2
−/−,2
 PFS,2
 tuberous sclerosis complex,2
Lymph node,2
 Population pharmacokinetics,2
carcinoma,2
Cancer survivor,2
 exosomes,6
 Harmonization,2
 lymphangiogenesis,2
 Cardiovascular disease,2
 proteomics,7
 Quercetin,2
 chemotherapy,31
 Lung,36
Adenocarcinoma,29
Adverse events,3
EGCG,2
Diabetes,3
 dendritic cell,2
HER2,2
 tumor microenvironment,10
 lung cancer stem cells,3
 Radiology,3
Video-assisted thoracoscopic surgery ,4
 Female,2
 Inflammatory myofibroblastic tumor,2
 Napsin-A,2
 lung metastases,4
Computed tomography ,3
 polo-like kinase,2
Combined pulmonary fibrosis and emphysema,2
Non-small-cell lung cancer,2
 Integrin,2
 Therapy,5
 Osimertinib,4
Colorectal cancer,22
 cell death,2
 Alectinib,4
immune checkpoint inhibitors,2
 Mortality,16
 Cisplatin,11
 TB,2
DNMT1,2
 malignant pleural mesothelioma,8
 neoplasm,3
 radiation-induced lung injury,5
 Topotecan,3
 first-line therapy,2
 emphysema,3
 silibinin,3
 pulmonary,2
Genotype,2
 targeted agents,2
 Wnt/β-catenin,3
 polyphenols,3
 Epidemiology,16
 Quality indicators,2
 Pain,2
 poly,3
 tyrosine kinase inhibitor,12
 TNF,2
 MicroRNA,11
 progression,2
 Segmentectomy,5
IMRT,8
 Molecular targeted therapy,2
 Lungs,3
CT,14
 Computer-aided diagnosis,2
Antioxidant,2
 smoking cessation,5
 CTLA-4,2
 non-small cell lung carcinoma ,2
Anti-cancer,4
 Head and neck squamous cell carcinoma,2
 SLUG,2
Cancer registry,9
 cancer metabolism,3
Malat1,2
 gastric cancer,9
ctDNA,3
 Epithelial-to-mesenchymal transition,3
 neoadjuvant therapy,3
 lung development,2
 tumor suppressor,12
 cancer immunotherapy,4
SAHA,2
 intensity modulated radiotherapy,2
 antitumour,2
Carboplatin,4
 hemoptysis,2
 Tyrosine kinase inhibitor ,2
 metastatic melanoma,4
 Lung metastasis,10
SBRT,2
Crizotinib,5
EBRT,2
 ,4
II,6
ENB,2
COX-2,4
®,3
 thoracotomy,2
 Xenograft,2
 Esophagectomy,2
Chemoresistance,6
 Long noncoding RNA ,2
 Randomized trial,2
 everolimus,2
 programmed death-1,2
Afatinib,6
Antitumor activity,3
 Receptor tyrosine kinase,3
 P40,2
 non‐small cell lung cancer,4
 esophageal squamous cell carcinoma,2
 Quantification,4
 TNM,3
 Immunofluorescence,2
Lung metastases,3
 tumor suppressor genes,3
 Brachytherapy,3
 induction therapy,3
IGRT,2
 Tumor microenvironment,13
 Renal transplantation,2
 target therapy,3
 Lymph node metastasis,2
 Kidney cancer,2
CTLA-4,6
 Lung injury,2
 pleura,4
 miRNAs,3
 Postoperative radiotherapy,2
 Stereotactic body radiation therapy,3
 RPPA,2
 Carbon ion,2
 X-ray computed,5
CIK,2
 pneumonia,2
 mitomycin C,2
 computed tomography,9
 HNSCC,3
 distress,2
 airway stent,2
 Immunology and Microbiology Section,2
 NGS,5
 neuroendocrine differentiation,2
 Nanocapsules,2
 non-small-cell lung cancer ,6
LC,2
 TTF1,3
 mTORC1,2
 lung resection,4
Bronchopleural fistula,2
 lipid metabolism,4
 Docetaxel,4
 Triple negative breast cancer,2
 Metastatic spinal cord compression,2
Gene expression,4
 leptomeningeal metastasis,2
 small interfering RNA,2
 malignant,2
 Long noncoding RNAs,2
 Nickel,2
ERK1/2,3
 Biosynthesis,2
Cancer du poumon,2
 Cell cycle arrest,4
 miR-21,2
 Tumor progression,2
 SPECT,2
ROS,5
 Sarcopenia,4
Angiogenesis,20
Bone metastasis,4
 Malignant mesothelioma,6
 Graded prognostic assessment,2
 OS,4
 neuroblastoma,3
 Spinal metastases,3
 Ionizing radiation,4
 cohort studies,3
 astrocytes,2
 cancer treatment,3
 Dosimetry,4
 Survey,2
 PSA,2
 susceptibility,3
EBC,2
 Smoking cessation,8
 osimertinib,3
Smoking cessation,2
Cachexia,4
 Particle therapy,2
 flow cytometry,2
 LL-37,2
 cancer,60
 Pulmonary metastasectomy,6
FDG,3
 Risk factor,4
 Mice,3
 Non–small-cell lung cancer,5
 clinical practice,2
 Métastatique,2
breast cancer,15
Local recurrence,3
docetaxel,2
 Nanoparticles,7
 Mediastinal lymph nodes,2
 Molecular mechanism,2
PI3K,2
 STAT3,10
 stage III lung cancer,2
 epithelial cells,2
 Real time adaptive radiotherapy,2
Carcinoma,13
 protein-protein interaction,2
 Platinum,5
 Computer-aided detection,3
 Supportive care,2
 DNA damage,4
Brain metastasis,11
Lobectomy,7
 Predictive factor,2
 Lung development,4
AZD9291,4
 IPF,2
 Prognostic factor,5
AML,2
 obesity,4
 stage III,3
neoadjuvant chemotherapy,2
 Proliferation,33
FDG-PET,4
 Outcomes,6
 Matrix metalloproteinases,3
 c-FLIP,2
 KRAS mutation,4
 apoptosis,43
 Yeast,2
 Paraneoplastic neurological syndromes,2
CSCs,3
 Morbidity,2
 MYCN,2
 Immune checkpoint inhibitor,2
 pulmonary drug delivery,2
 TTF-1,2
 breath-hold,2
 Perfusion,2
 Erlotinib,22
 oxaliplatin,2
 pharmacogenomics,2
 warfarin,2
 Cell cycle,8
SIADH,2
 wedge resection,4
 Pulmonary hypertension,4
 air pollution,2
 prediction,2
Gene therapy,3
 metastasis,98
 Survie,2
 Tyrosine kinase inhibitor,10
Adjuvant chemotherapy,5
 Extracellular matrix,3
 Pleuropulmonary blastoma,3
Pathology Section,2
 Cancer immunotherapy,3
 endothelial cells,2
 MDM2,2
Chest CT,3
 Gene therapy,3
 cell migration,6
 second-line,2
 Corticosteroids,2
 Curative resection,2
 Transforming growth factor β1,2
 CT,3
 cytotoxicity,18
 innate immunity,2
 multiple pulmonary nodules,2
 First-line,2
 long noncoding RNA,2
 multimorbidity,2
Single-port,2
lung squamous cell carcinoma,2
 Safety,4
 Prostate,3
adjuvant chemotherapy,2
 neoplasms,6
Epidermal growth factor receptor mutation,2
 Solitary fibrous tumor,3
 Organs at risk,3
 overall survival ,2
 caspase,2
 Reactive oxygen species,8
 Tolerance,2
 lung nodule,4
 RNA-seq,2
 Paraneoplastic neurological syndrome,2
MALAT1,8
 YAP,2
 Korea,6
 Methylation,3
 Smoking Caused Disease,2
 Semaphorin 3A,2
BRCA1,3
 lung disease,2
 P53,3
 food effect,2
ALK inhibitor,4
 Postoperative care,3
lncRNA,2
Complications,4
Case report,9
 Circulating tumor cells,4
 NHLBI,2
 non–small-cell lung cancer,2
Lung cancer surgery,4
 VATS,8
 Video-assisted thoracic surgery,5
 Flavonoid,3
Acute lung injury,2
 Rechallenge,2
IL-10,3
IL-17,3
 survival rate,3
 Multidrug resistance,3
 lymph node metastasis,2
 GRP78,2
 histone acetylation,2
miRNA,4
 Postoperative complications,2
 positron emission tomography,7
 unknown primary,2
 classification,2
 anaplastic lymphoma kinase,5
 Vinorelbine,4
 Hedgehog pathway,2
 SBRT,14
China,4
 Immune system,2
 pembrolizumab,15
Elderly,7
 pneumonectomy,3
 nasopharyngeal carcinoma,5
ALDH1A1,2
 ERK,2
 Thoracic radiotherapy,3
 risk factors,4
 clinical,2
 Prognostic factors,9
Alcohol,2
 Heterogeneity,3
Circulating tumor DNA,2
 micelles,2
 Polycyclic aromatic hydrocarbons,3
ALK inhibitors,3
 research,2
lobectomy,3
 usual interstitial pneumonia,2
 Sunitinib,2
 immune checkpoint inhibitors,2
Alternative splicing,2
 Gatekeeper mutation,2
Droplet digital PCR,2
 Prophylactic cranial irradiation,4
 Lung cancer mortality,3
 Pleural effusion,8
 Cell proliferation,6
 Uniportal,2
drug resistance,3
 HER-2,2
 precision medicine,5
 tumors,2
 stereotactic radiosurgery,7
 mutation,19
 skin,3
 RRx-001,2
 neuroendocrine,3
 PD-L2,2
Anti-tumor activity,3
 Next generation sequencing,4
 metformin,2
 HER2,3
 HER3,2
 malignant pleural effusion,4
 Luteolin,2
 Incidence,5
 advanced non-small-cell lung cancer,2
 SGLT2,2
Anatomic lung resection,3
 mRNA,5
 Folliculin,3
 mouse models,2
everolimus,4
 Developing countries,2
 Squamous cell lung cancer,3
 Dermatomyositis,3
fine needle aspiration,2
 MET exon 14 skipping,2
cisplatin,4
A549 cell line,2
 COPD,6
T790M,2
 epidermal growth factor,2
 small cell lung carcinoma,7
 Methodology,2
 CDDP,2
 Ventilator-induced lung injury,2
 clinical trial,4
 ultrasound,2
 Screening,13
 Resveratrol,4
 Radiation,9
 reactive oxygen species,6
 myeloid-derived suppressor cells,2
 estrogen receptor,4
 Breast cancer,14
Cancer incidence,3
 sabr,2
 Pleural Disease,2
 LncRNA,3
 Small cell lung cancer,21
 alternative splicing,2
 NF-κB,6
 logistic regression,2
 Lung cancer screening,7
 Oncogenesis,2
 EBUS-TBNA,2
 NSCLC,178
 mouse model,3
 ctDNA,4
 alectinib,3
 MET,5
bevacizumab,7
 thymoma,4
carboplatin,2
Uniportal,3
 regulatory T cells,2
Lung Cancer,3
 topotecan,2
Companion diagnostics,2
 Radiation dose reduction,2
 vascular endothelial growth factor,5
 Immune checkpoint inhibitors,3
 Silicosis,4
 Thioredoxin,2
 Cancer stem cell,5
 Pulmonary metastases,2
 microenvironment,5
 antiproliferative activity,2
 Leukemia,2
 Tumor-infiltrating lymphocytes,2
 senescence,3
angiogenesis,6
 stereotactic radiotherapy,2
 Radiography,4
 occupational exposure,2
 antitumor,2
 Multimodality treatment,2
 Immune therapy,3
 texture analysis,2
 regulation,3
 depression,6
 Re-irradiation,3
 toxicity,8
combined pulmonary fibrosis and emphysema,2
 immunosuppression,4
 lipid synthesis,2
 ubiquitination,4
chemoresistance,3
 Chimioradiothérapie,2
Cigarette smoke,2
 Quantitative proteomics,3
 Occupational disease,2
 Lung cancer,334
 Nonsmall cell lung cancer,2
 Pyruvate dehydrogenase kinase,2
 targeted therapies,4
 Lung cancer surgery,10
 Multidetector computed tomography,4
 influenza,3
 stage I,2
carcinogenesis,2
IHC,6
 head and neck cancer,3
 Phase I,2
 Tomography,3
Pleural effusion,2
Allergy,2
 vomiting,2
 Gefitinib,14
anaplastic lymphoma kinase,8
 Serum,4
 Human epidermal growth factor receptor 2,2
 asbestos,5
 Mammalian target of rapamycin ,2
 Non-small-cell lung cancer ,3
 sickle cell disease,3
Biopsy,3
 Monte Carlo simulation,2
 Invadopodia,2
 Checkpoint inhibitors,2
 TP53,5
 opioids,2
 single nucleotide polymorphism,7
 SRS ,3
MS,2
OS,2
 Lung nodules,3
 Lung neoplasms,25
 antitumor activity,4
 Children,2
 lung cancer screening,4
 hyaluronan,2
 PCBP1,2
Chemoradiotherapy,8
 Antibacterial,2
 quality of life,10
 Motion management,2
chronic obstructive pulmonary disease,4
 Pemetrexed,9
 cohort study,4
 Computed tomography,9
 lung cancer surgery,4
 retinoblastoma,2
 safety,2
 multimodality therapy,3
 VEGFR2,4
 nonsmall-cell lung cancer,2
 Recurrence,16
KRAS mutation,2
Adhesion,5
SEER,2
CRC,4
 Pathology Section,2
 PET/MRI,5
 resection,6
 Hospital care,2
 acute myeloid leukemia,2
 antioxidant,2
 Ramucirumab,2
AXL,2
 Eribulin,3
 inflammation,23
 biopsy,6
 Breast,3
TNM classification,2
 hepatocellular carcinoma,3
gefitinib,4
 Stereotactic radiosurgery ,2
 paclitaxel,11
 video-assisted thoracic surgery ,7
 molecular imaging,5
 microarray,2
 epidermal growth factor receptor ,10
Drug resistance,4
 Target volume delineation,3
biopsy,3
 Prevalence,3
Advanced,3
 human,4
 Cell growth and migration,2
 cancer microenvironment,2
ALDH,3
 mitochondrial membrane potential,2
cardiac surgery,2
 lymph node,2
 Stereotactic body radiotherapy,4
 docetaxel,6
Cell-free DNA,4
 LDH,2
 Risk,5
 Radiosensitization,2
 endocrine resistance,2
 lung carcinogenesis,2
 Colorectal cancer,7
 4D-CT,2
 Pancreas,3
 SILAC,3
 Liver metastasis,2
Cell cycle,8
 Stage III,4
 stereotactic laser ablation,2
Adults,3
 Paraneoplastic syndrome,4
 cancer therapy,2
 quantitative proteomics,2
 Prognostic marker,5
 transcriptomics,3
NF-κB,3
 brain metastasis,11
 Rehabilitation,4
 breast cancer,32
 Pneumonitis,2
 morphology,2
 triple-negative breast cancer,4
ALK,37
 RNAi,5
Atrial fibrillation,3
E-cadherin,6
 mTOR,9
 Chemoresistance,4
 Anticancer,6
 driver mutation,3
 liver metastasis,4
Lung adenocarcinoma,6
 antimetabolites,2
 Postoperative recurrence,2
 Chylothorax,2
 tyrosine kinase inhibitors,7
 Cytoskeleton,2
 Hypoxia,8
Antiproliferative activity,4
 solid lipid nanoparticles,2
 esophageal neoplasms,3
 liver,4
 Chemotherapy,22
 Genetics,2
 Methods,3
 acetylation,2
Small cell lung cancer,2
 Sarcoma,4
 asbestosis,2
 crizotinib,18
 acquired resistance,6
Cisplatin,11
 mammalian target of rapamycin,2
 chemokines,2
 tumorigenesis,7
Notch,2
 thoracic radiotherapy,2
 Lung diseases,3
Patient-reported outcome,2
 Carcinoma,6
 Systemic therapy,2
 Antiproliferative activity,2
 G,2
 zebrafish,2
 Gemcitabine,3
 Geriatric,2
 L858R,3
CT images,2
 Risk factors,10
 circulating tumor DNA,2
KRAS,9
 Lymph nodes,2
 small cell carcinoma,2
 Non-small cell lung cancer,151
CDDP,2
Bevacizumab,8
 Tumor cells,2
Early detection,4
 genomics,2
FGFR1,2
 prostate cancer,13
VEGF,3
 ER stress,2
 Thoracic surgery,15
 Lung Neoplasms,2
 Vaccine,2
Asthma,2
 erlotinib,14
antitumor agents,2
 PET/CT,18
 PET-CT,4
 outcomes,5
Cancer cachexia,2
Adult,3
ABCG2,3
EMT,22
 dyspnea,3
 signaling pathways,2
 MAPK pathway,2
 Ethanol,2
 clinical trials,5
 nanomedicine,3
VATS,26
 symptoms,2
 MUC1,3
 Primary tumor,2
GWAS,2
 Selumetinib,2
 Tumor,6
 Korean,2
 thoracic,2
 venous thromboembolic events,2
 colorectal,2
 robotic,3
 Spontaneous pneumothorax,2
 pulmonary resection,2
 quercetin,4
 Liposome,3
 Health,2
Epidemiology,4
 ipilimumab,3
 prognosis,89
 Respiratory gating,2
 PET imaging,3
EGFR TKI,3
 osteoporosis,2
 Gene expression,5
 Vertebrectomy,2
 Nab-paclitaxel,3
 Lung tumors,3
Adenocarcinoma in situ,3
 DICER1,2
 phosphorylation,4
 doxorubicin,5
 Acquired resistance,2
Hepatocellular carcinoma,2
Breast cancer,31
chronic disease,2
 metastatic disease,4
chemotherapy,18
 Ovarian cancer,5
 transcription,2
4-,4
 Heparin,2
 interferon,2
 Stage I,3
 radioimmunotherapy,2
 bevacizumab,8
 MYC,3
 aneuploidy,2
Cancer metastasis,2
 Cell death,3
 Cell migration,3
EGFR TKIs,2
 Tumor proliferation,2
 VEGFR,2
 HIV,4
 chronic kidney disease,3
 Glomus tumor,3
 volumetry,2
 pleural effusion,3
 histology,8
Cancer pain,2
EGFR-TKIs,3
 exacerbations,2
asthma,2
 Pulmonary disease,2
Caveolin-1,2
 bronchial neoplasms,2
 asthma,6
 stereotactic body radiotherapy,5
 Cyclophosphamide,2
 Small cell lung cancer ,4
FISH,3
 Flattening filter free,2
 Proton therapy,3
 inhalation,2
 Mode of action,2
 review,9
 first-line,3
 microRNA,20
 SEER,5
 Metastatic,5
 non-small-cell lung,6
 urine,2
 nanotechnology,3
Bronchoalveolar lavage fluid,3
 Reactive mesothelial cells,2
Asbestos,10
 plasma,3
Imaging/CT MRI etc,4
Co-expression,2
 Mouse,3
 TGF-β1,6
 MicroRNAs,3
 Incidental,2
 smokers,2
 extracellular matrix,5
 herbal medicine,4
 Stem cell transplant,2
 TPGS,3
 Copy number gain,2
 Espindolol,2
chemoradiotherapy,6
 matrix metalloproteinases,2
 lung squamous cell carcinoma,6
 Fluorescence in situ hybridization,4
 uniportal,2
 drug delivery,9
DNA repair,5
Chinese,2
 Oncogenic drivers,3
 solid,2
 radiotherapy,35
 malignant melanoma,2
 targeted delivery,2
 EML4-ALK,5
 nivolumab,16
 Lung squamous cell carcinoma,6
 targeted therapy,26
 Mcl-1,2
 drug discovery,3
 Ubiquitination,2
Chemoradiation,6
 Validation,4
4D-CBCT,2
 therapy,7
 computer-assisted,2
 sulforaphene,2
 Noncoding RNA,2
 lung cancers,2
 Nucleoside,2
Non-small cell lung cancer ,13
 Renal cancer,2
 lung cancer ,2
 signal transduction,7
 Sublobar resection,2
 protein degradation,2
 TEP,2
 miR-214,2
 Metabolomics,3
 Adénocarcinome,2
 p16,3
 NFATc1,2
 radioresistance,3
 Human papillomavirus,2
 Methotrexate,3
 Pulmonary nodule,7
 Platinum-based chemotherapy,2
 Tyrosine kinase inhibitors,8
VATS lobectomy,4
Cancer cells,2
 RET,3
 Bevacizumab,3
 Menopause,2
 Lymphoma,2
 Long non-coding RNA,6
 brachytherapy,2
18F-FDG PET/CT,4
 Oncogene,3
 Lactate dehydrogenase,2
Esophageal cancer,4
 K-ras,2
Desmocollin-3,2
 Mesothelioma,23
 Serum biomarkers,3
Erlotinib,5
asbestos,3
Clinical trial,3
EGFR mutation,10
Diagnostic,2
 kinases,2
 checkpoint inhibition,2
 carcinoid,2
 TGFβ,2
 Overexpression,3
 Histopathology,2
Mesothelioma,7
TSA,2
 tuberculous pleural effusion,2
BAP1,4
 Phosphorylation,2
 vimentin,2
 Effusions,2
SCLC,11
brain metastases,3
 Radiosurgery,4
 Surgical resection,3
 Exosome,3
 personalized medicine,9
Chronic obstructive pulmonary disease,3
 ERK1/2,2
 surgical management,2
Cryoablation,3
 MRI,6
 lung metastasis,9
 metastasectomy,3
 Time trends,2
 Complication,3
biomarker,3
 Subtypes,2
 Chirurgie,2
QoL,2
 SUVmax,2
 monoclonal antibodies,2
 cytology,5
 ovarian cancer,9
Breast neoplasms,3
 arterial thromboembolic events,2
 pancreatic cancer,6
 Combination therapy,5
 Crizotinib,17
Classification,3
 rearrangement,2
 Radiation pneumonitis,9
 VMAT,6
 lung squamous carcinoma,2
 mitophagy,2
Immunohistochemistry,7
 Outcome,3
 kinase inhibitor,3
 Transbronchial needle aspiration,2
 lobectomy,16
 Calcium,2
 marker,2
 Lung disease,3
Doxorubicin resistance,2
 Pulmonary emphysema,3
 TGF-β,6
lung adenocarcinoma,4
 Escherichia coli,3
 platinum,6
 tumor associated macrophages,2
 regorafenib,2
 Biomarkers,3
 Monoclonal antibody,4
 immunoPET,2
 Overall survival,12
 Tumor-associated antigens,2
Acquired resistance,4
 Src signaling pathway,2
 Neuropathy,2
 innovation,2
 KPS ,2
 glucocorticoids,2
 one-lung ventilation,2
 cardiotoxicity,2
 single nucleotide polymorphism ,2
 arsenic,2
 chemoradiotherapy,4
bone,2
 flavonoids,2
 Endometrium,2
 cytokines,4
 proton therapy,3
 Galectin-1,2
 patient navigation,3
 Biopsy,2
Antiproliferative,2
 Steroids,2
 Evidence-based medicine,2
 Lung carcinoma,4
Bladder cancer,3
 Tobacco control,2
 sbrt,3
 Programmed death-ligand 1,2
 radon,3
 Trastuzumab,3
 CTCs,2
3-dioxygenase,3
 combination,2
Chemotherapy,38
 P-gp,3
 EGFR mutation,13
 Male,2
 tumour microenvironment,2
 prevalence,6
 ursolic acid,2
Ewing sarcoma,2
 serum,3
 animal models,2
 Segundos tumores primarios,2
 SOCCs,2
Anaplastic lymphoma kinase ,4
 tobacco use,2
 Nicotine,2
Epithelial–mesenchymal transition,2
Comorbidity,3
 survivorship,2
 Venous thromboembolism,2
 radiation therapy,12
 human relevance,2
 Immunohistochemistry,24
biomarkers,4
 PTEN,8
 surgery,26
epidermal growth factor receptor,9
 Skeletal-related event,2
 Mediastinum,4
 malignant mesothelioma,5
 Predictive biomarkers,4
 Skin,2
 mitosis,2
 PI3K/AKT,2
 Neoplasms,11
 actin,2
 Hospital mortality,2
 Radiation therapy,12
 molecular docking,2
 ceritinib,7
 overall survival,15
 regulatory T cell,2
 radiation pneumonitis,5
 Population-based,3
 Lung nodule,3
 FDG PET/CT,3
 Neutrophil-to-lymphocyte ratio,2
 photothermal therapy,2
 registries,2
 network,3
 chronic obstructive pulmonary disease ,2
 p40,2
 Radiation dose,3
Chylothorax,2
 hyperthermia,3
 atezolizumab,2
 Radiotherapy,41
FDG PET/CT,2
 IP-10,2
distant metastasis,2
Bone metastases,5
epidemiology,2
 Risk assessment,5
 Cerebrospinal fluid,2
 Solid tumor,2
 exposure assessment,2
B7-H3,3
 pulmonary function,4
 Paclitaxel,7
 Palliative care,6
 Quality of life,11
 nanostructured lipid carriers,2
 meta-analysis,43
 nintedanib,3
 squamous cell lung cancer,4
18F-FDG,4
 Carbon nanotubes,2
 carcinoembryonic antigen,2
 Malignant pleural effusions,2
 total lesion glycolysis,3
 synergism,2
diagnosis,2
 cell proliferation,9
 Ovary,2
 RTEL1,2
 expression,4
 smoking,7
 Tissue distribution,2
 non-small cell lung cancer,146
 pediatric,2
 Malignant pleural effusion,3
 Twist,2
 Molecular docking,3
 Immune cells,2
 Antimicrobial activity,2
 Leptomeningeal metastasis,5
 Thyroid cancer,5
 receptor,2
Clinical trials,3
Management,2
 gemcitabine,4
 skin cancer,2
 Fluorescent in situ hybridization,2
 thoracoscopic surgery,2
 Gefitinib resistance,2
 Positron emission tomography,7
 progression-free survival,2
Distant metastasis,2
EZH2,2
 Video-assisted thoracoscopic surgery,5
 Helical tomotherapy,3
chondrosarcoma,2
early detection of cancer,3
 interstitial lung disease,9
 sleeve lobectomy,2
 Macrophage,3
 Survival,52
 Keap1,2
 ventilator-induced lung injury ,2
 vascular endothelial growth factor ,2
 Autophagy,19
Prognostic factors,2
 pathway,2
 Lung tumor,2
 topoisomerase inhibitors,2
 prognostic,3
 Drug resistance,3
 maintenance treatment,2
 Maintenance therapy,2
 tumor growth inhibition,2
 immune function,2
AIDS,2
cytopathology,3
 whole-exome sequencing,3
 Free circulating DNA,2
 neutrophil,2
 Carcinogenesis,2
 Small-cell lung cancer,11
 Infection,2
 optimization,2
 quality,3
 Intensity-modulated radiation therapy,2
 Sox2,2
 thyroid,2
 Mesenchymal stromal cells,2
 Melanoma,15
,8069
 MMP9,3
 STAT1,2
Curcumin,3
non-small cell lung cancer,3
 KRAS,20
 Thrombosis,2
Acid sphingomyelinase,2
 Anticancer activity,2
 Imaging,5
 tumor response,2
 Radiothérapie stéréotaxique,2
 Lung cancer cells,4
 Estrogen receptor,2
MPM,2
 Non-small-cell lung cancer,29
 cancer stem cell,3
 TKI resistance,2
Biomarker,24
 PM,3
 Palliative radiation,2
 survival analysis,2
 miR-155,4
 Vaccines,2
 single-port,3
NGS,2
 adverse drug reaction,3
 Synergy,3
 entinostat,2
 Stat3,3
 surgical treatment,3
 tumor progression,2
 malignancy,6
 Mouse model,3
 NIK,2
 heparan sulfate proteoglycan,2
 Radiothérapie,6
 confidence interval,2
 Drug delivery systems,2
 methylene blue,2
 Pneumonectomy,9
 heart,2
 Thioredoxin reductase,2
 pulmonary embolism,3
 Low-dose CT,2
 immunohistochemistry,30
 differential diagnosis,2
 lung cancer cells,5
 patient education,2
 TCGA,2
 PD-L1,31
 Molecular imaging,2
 chromatin,2
 mesothelioma,15
 MALAT-1,2
 Oct-4,2
 Pulmonary metastasis,6
 Sequencing,2
 Therapeutic approach,2
 Rat,2
 venous thromboembolism,3
 Efficacy,3
 Etoposide,3
 metastatic,6
curcumin,3
 Chemoradiotherapy,2
Conformal radiotherapy,2
 PERCIST,2
 radiation dose,2
 management,3
 PM2,2
 anticancer activity,3
 Caspase,2
Autophagy,3
 Superior vena cava syndrome,2
 Depression,2
erlotinib,2
 microRNAs,6
 DNA methylation,11
Genetics,2
 N2,2
 diagnostic value,2
 JNK,4
 Immune checkpoint,2
 uPAR,2
 Inflammation,11
 focal adhesion,2
 Nanomedicine,4
 dermatomyositis,2
CABG,2
 Ki-67,2
 Survival outcome,2
 Regulatory T cells,2
 Cytotoxic activity,6
 Cisplatin ,3
 FISH,6
Incidence,5
cancer,27
Anticancer,5
Medicare,3
 fine-needle aspiration,2
 ionizing radiation,4
Hippo pathway,3
 video-assisted thoracoscopic surgery ,4
 neoadjuvant chemotherapy,3
 intensity-modulated radiotherapy,3
 Image processing,2
Antibodies,3
 preterm birth,2
 Tumor-associated macrophages,2
 FFPE,3
Lung cancer,79
 radiation,3
 Interferon-γ,2
Small-cell lung cancer,2
 CYP3A5,2
 Scoring system,2
 PI3K,4
 ErbB,2
 oncogene,3
 osteosarcoma,10
 Total body irradiation,3
 myeloid cells,2
 Progression-free survival,6
 invasion,26
 Afatinib,4
CCND1,2
 Deformable image registration,2
 Nivolumab,13
 neuroendocrine tumor,4
 programmed death ligand-1,2
 Genotoxicity,4
 urothelial cancer,2
 Japan,3
 Pulmonary nodules,4
 Epithelial-mesenchymal transition,6
adolescent,3
 Neuroendocrine carcinoma,2
Advanced lung cancer,2
ALK-positive NSCLC,2
 Diagnostic,2
 PD-1,23
 Met,2
 EML4–ALK,3
 Src,2
 Squamous cell carcinoma,12
Bombesin,2
 neutrophils,2
 quality of life ,2
 Prevention,4
 oncogenes,2
PD-L1,7
Cost-effectiveness,4
 Malignancy,4
 liquid biopsy,8
 lung surgery,2
 detachment,2
 Magnetic resonance imaging,4
 gene expression profiling,3
lung cancer,19
 Lymph node,2
 Merkel cell carcinoma,2
 neuroendocrine carcinoma,2
 survival,28
 colon cancer,5
mTOR,2
 Urothelial cancer,2
 β-catenin,6
 Choroidal metastasis,2
 Oncology,3
 Liver metastases,4
 Non-small cell lung cancer ,11
 iron oxide nanoparticles,2
 Growth,2
 Immunity,2
COPD,26
SABR,3
 CBCT,2
 Targeted therapies,4
EGFR-TKI,5
 Single nucleotide polymorphisms,2
CXCR4,3
 ulinastatin,2
 brain tumor,2
 apatinib,2
T790M mutation,2
 lung neoplasms,16
 Idiopathic pulmonary fibrosis,4
 leukemia,2
 molecular,2
 brain metastases,7
 Loss of heterozygosity,2
 tyrosine kinase inhibitor ,2
 palliative care,7
 Biomarker,7
 EGCG,2
Acute respiratory failure,2
 resistance,13
 Oligometastases,2
 Morphology,3
 Stromal cells,2
 c-MET,3
AUC,3
 gefitinib,22
 Monoclonal antibodies,3
 combination therapy,7
Anti-tumor immunity,2
 Precision medicine,3
 biodistribution,4
 endobronchial ultrasound,2
 Slug,2
Breast Cancer,2
 platinum-based chemotherapy,2
EBUS-TBNA,2
 aging,4
 epigenetic,3
 Surgery complications,2
 liver metastases,2
 Myrtaceae,2
 Thailand,2
 Thoracoscopic lobectomy,2
 Thymidylate synthase,2
 Surgery,34
 Lung neoplasm,3
 TLR4,3
 Radiosensitivity,5
 Mitochondria,3
 adenovirus,4
 camptothecin,3
 Epidermal growth factor receptor,9
 MLC tracking,2
 biomarker,23
 human papillomavirus,5
 cancer screening,2
Computed tomography,14
 PLK1,2
 Apoptosis,25
 SNP,6
 Image interpretation,2
Colorectal cancer ,2
Lewis lung carcinoma,3
 extracellular vesicles,2
 Hemodialysis,2
 EGFR,44
 wound healing,3
 stereotactic body radiation therapy,6
 CSCs,2
 gallbladder cancer,2
 Spine,5
Gemcitabine,2
NSCLC,120
 Aryl hydrocarbon receptor,2
 tyrosine kinase inhibitors ,2
 diabetes,3
 China,3
 thoracic surgery,6
 Shared decision making,3
 Neoadjuvant chemotherapy,2
 spinal cord,2
 lung adenocarcinoma ,3
ZEB2,2
Basal cell carcinoma,2
 cancer mortality,2
 adhesion,2
 and End Results ,2
 Smoking,19
 Non–small cell lung cancer,8
 Th17,2
 Diagnosis,18
 Non-small cell lung carcinoma,8
 ROS1 rearrangement,2
 brigatinib,2
 Head and neck cancer,2
 Whole-body,2
 respiratory function tests,2
 Esophageal cancer,2
 public health,4
Data mining,2
 Transferrin,2
 Qualitative,2
 invasive mucinous adenocarcinoma,2
 Brain,2
 Colorectal,4
 bronchoscopy,7
 magnetic resonance imaging,4
 Stem cells,2
 systematic review,9
 Thromboembolism,2
 complexes,5
SUV,2
Cell proliferation,8
NTCP,2
 IGF1R,2
 Bronchoscopy,5
adenoid cystic carcinoma,2
 siRNA,5
 Stress,2
 Doxorubicin,2
 Mesenchymal stem cells,3
 Oxidative stress,6
 Gallic acid,2
 phenotyping,2
 Stereotactic ablative radiotherapy,3
 renal cell carcinoma,9
 Predictive factors,2
 angiogenesis,11
Advanced non-small-cell lung cancer,2
 metabolic tumor volume,2
 Xanthones,2
 liposome,2
 synergistic effect,3
Migration,2
 pulmonary nodule,4
 Purkinje cells,2
Lung neoplasms,7
Cytotoxicity,3
cell-free DNA,2
Gastric cancer,5
DNA damage,9
PORT,2
 Unfolded protein response,2
 predictive biomarkers,2
NPC,2
 ground glass opacity ,4
 ROS,10
 EGFR mutations,3
 Renal cell carcinoma,11
 Glycolysis,2
 EWSR1,2
 Pyrosequencing,2
 interferon-γ,3
 Zinc,2
 miR-124,2
 Lung metastases,5
 TRAIL,7
 Survival rate,2
SRS,2
 Phase I study,2
 DNA binding,3
 non-small cell lung,2
 Histology,3
